Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

March 15, 2022

Conditions
Uterine NeoplasmsCervix NeoplasmsBladder NeoplasmsProstatic Neoplasms
Interventions
PROCEDURE

MRI contrast agent Combidex (ferumoxtran-10)

Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Princess Margaret Hospital, Canada

OTHER

lead

University Health Network, Toronto

OTHER

NCT00188695 - Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | Biotech Hunter | Biotech Hunter